Kukje Pharma국제약품
002720 · KOSPI · ₩002720 · 국제약품
₩3,345▼ ₩55 (1.62%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩175B | ₩156B | ₩135B | ₩127B | ₩120B |
| Cost of sales | ₩82B | ₩74B | ₩68B | ₩63B | ₩65B |
| Gross profit | ₩94B | ₩82B | ₩67B | ₩63B | ₩54B |
| Operating income | ₩6.2B | ₩6.7B | −₩2B | ₩5.3B | −₩1.7B |
| Net income | ₩5.7B | ₩5.2B | −₩8.4B | ₩3.5B | −₩1.6B |
| Net income to shareholders | ₩5.7B | ₩5.2B | −₩8.4B | ₩3.6B | −₩1.6B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩182B | ₩166B | ₩163B | ₩137B | ₩140B |
| Current assets | ₩67B | ₩57B | ₩55B | ₩49B | ₩48B |
| Cash and equivalents | ₩11B | ₩8.7B | ₩11B | ₩5.5B | ₩7.9B |
| Total liabilities | ₩85B | ₩76B | ₩78B | ₩63B | ₩71B |
| Current liabilities | ₩62B | ₩29B | ₩60B | ₩48B | ₩55B |
| Borrowings | ₩27B | ₩29B | ₩30B | ₩27B | ₩34B |
| Total equity | ₩98B | ₩90B | ₩85B | ₩74B | ₩69B |
| Shareholders' equity | ₩98B | ₩90B | ₩85B | ₩74B | ₩69B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩5.8B | ₩3.9B | ₩3.6B | ₩6.5B | ₩9.6B |
| Capital spending | ₩3.6B | ₩2.9B | ₩1B | ₩1.3B | ₩1.9B |
| Free cash flow | ₩2.2B | ₩1B | ₩2.5B | ₩5.2B | ₩7.7B |
| Dividends paid | ₩611M | — | — | — | ₩0 |
Consolidated where available. Amounts in won.
Also known as: Kukje Pharma / 국제약품 / 002720 / KRX:002720
Source: KRX statistical information